Project Grant K23AA033444
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Colorado-Denver $189,532 on August 19, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop and test a peer-narrated video decision aid for alcohol treatment tailored to intensive care unit survivors with alcohol use disorder. The award funds a five-year career development project (K23) led by Dr. Kelsey Hills-Dunlap. The research addresses a gap identified in prior work: ICU survivors with alcohol use...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $191,509 on August 20, 2026, under the Alcohol Research Programs (CFDA 93.273) to adapt and pilot test a care navigation intervention for hospitalized patients with alcohol use disorder. The award funds adaptation and pilot testing of the Navigation for Prioritized Alcohol Treatment After Hospitalization (NAVPATH) intervention, which...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $587,958 on August 10, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct a longitudinal sibling-comparison study of alcohol use disorder and co-occurring externalizing problems in high-risk individuals. The research follows 559 mid-adulthood participants with high prevalence of alcohol use disorder (67%), arrest history for...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $140,340 on December 1, 2025, under the Alcohol Research Programs (CFDA 93.273) for a Project Grant investigating the role of the C5 complosome in ethanol-induced immunometabolic dysregulation of Kupffer cells in alcohol-associated liver disease. The funded research defines novel mechanisms of alcohol-induced metabolic reprogramming of Kupffer...
- The National Institute on Alcohol Abuse and Alcoholism awarded Loyola University of Chicago Health Sciences Campus $115,500 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to identify leading causes and pathways of death in alcoholic acute respiratory distress syndrome (ARDS) patients through computational analysis of clinical trial datasets. The recipient will conduct a retrospective cohort study validating findings across five NIH-funded, multicenter, randomized,...
- The National Institute on Alcohol Abuse and Alcoholism awarded Cedars-Sinai Medical Center $1.235 million under the Alcohol Research Programs (CFDA 93.273) on September 10, 2025, to investigate the role of prohibitin 1 (PHB1) in ethanol's sensitizing effect on colorectal liver metastasis. Research will examine how excessive alcohol intake depletes hepatocyte nuclear and cytosolic PHB1, increasing matrix metalloproteinase-7 (MMP-7) expression and rendering the liver susceptible to colorectal...
- The National Institute on Alcohol Abuse and Alcoholism awarded Duke University $2,725,992 under the Alcohol Research Programs (CFDA 93.273) on September 1, 2026, to assess the impact of three employer-sponsored strategies on alcohol use disorder (AUD) detection, treatment, and health outcomes among working-age adults with private insurance. The project will evaluate whether expanding clinician provider networks, reducing out-of-pocket financial barriers to care, and implementing...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $576,197 on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop and test a digital pill system paired with smartphone-delivered cognitive behavioral therapy to measure and support acamprosate adherence in individuals with alcohol use disorder and alcohol-associated liver disease. Yale will develop a user-centered adherence intervention called ACAMPROSYNC that combines a digital pill system...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $3.23 million Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273). This four-year research project, concluding August 31, 2029, will investigate the effects of full-spectrum cannabidiol (CBD) on alcohol consumption and alcohol use disorder (AUD) phenotypes to inform precision medicine approaches. The research...
The National Institute on Alcohol Abuse and Alcoholism awarded the University of Colorado-Denver $191,592 on August 19, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a five-year mentored research project on enhancing emergency department care for alcohol use disorder. Dr. Jacob Lebin will develop and test an electronic health record-embedded clinical decision support tool designed to improve identification and treatment of alcohol use disorder in emergency department settings. The project uses a user-centered design approach and implementation science framework to iteratively develop and evaluate a clinical decision support system that integrates medications for alcohol use disorder—naltrexone and acamprosate—and social work interventions into routine emergency department workflows. Study activities include qualitative investigation through patient interviews and clinician focus groups to identify key components and intuitive language for the tool, and development and iterative optimization of an EHR-based prototype using rapid-cycle, user-centered design methods. The project supports Dr. Lebin's career development and transition to research independence as an independent health services researcher. Performance occurs in Aurora, Colorado, with an ultimate completion date of July 31, 2031. This is a Project Grant, a form of assistance funding under the Alcohol Research Programs, which supports fundamental knowledge development applicable to improved treatment methods and prevention strategies for alcoholism and alcohol-related problems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $191.6k | 8/21/26 |